Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by 180 Life Sciences Corp.
180 Life Sciences Announces Positive Topline Results of a Clinical Pharmacology Study Testing a New Solid Formulation of CBD with Enhanced Oral Uptake
July 30, 2024
From
180 Life Sciences Corp.
Via
GlobeNewswire
Tickers
ATNF
180 Life Sciences Granted an Additional Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements
July 23, 2024
From
180 Life Sciences Corp.
Via
GlobeNewswire
Tickers
ATNF
180 Life Sciences Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements
July 02, 2024
From
180 Life Sciences Corp.
Via
GlobeNewswire
Tickers
ATNF
180 Life Sciences Regains Full Compliance with Nasdaq Minimum Bid Price Requirement
March 14, 2024
From
180 Life Sciences Corp.
Via
GlobeNewswire
Tickers
ATNF
180 Life Sciences Corp. Announces 1-For 19 Reverse Stock Split as Part of Nasdaq Compliance Plan
February 26, 2024
From
180 Life Sciences Corp.
Via
GlobeNewswire
Tickers
ATNF
180 Life Sciences Engages Financial Advisor to Explore Strategic Alternatives
December 04, 2023
From
180 Life Sciences Corp.
Via
GlobeNewswire
Tickers
ATNF
180 Life Sciences Announces Review of Strategic Alternatives
November 28, 2023
From
180 Life Sciences Corp.
Via
GlobeNewswire
Tickers
ATNF
180 Life Sciences Corp. Announces Closing of $3 Million Public Offering
August 14, 2023
From
180 Life Sciences Corp.
Via
GlobeNewswire
Tickers
ATNF
180 Life Sciences Corp. Announces Pricing of $3 Million Public Offering
August 10, 2023
From
180 Life Sciences Corp.
Via
GlobeNewswire
Tickers
ATNF
180 Life Sciences Announces an Agreement for a Clinical Pharmacology Study Testing a New Formulation of CBD for Enhanced Oral Uptake
August 07, 2023
From
180 Life Sciences Corp.
Via
GlobeNewswire
Tickers
ATNF
180 Life Sciences Provides Update on Regulatory Approval Process in the UK and US for Dupuytren’s Disease Treatment; Continues Consultations with the UK MHRA and Initiates a Type C Meeting Request With the US FDA
August 03, 2023
From
180 Life Sciences Corp.
Via
GlobeNewswire
Tickers
ATNF
180 Life Sciences Corp. Announces the Filing of a Provisional Patent Describing the Combination of CBD With GLP-1 Agonists to Suppress Appetite
July 31, 2023
From
180 Life Sciences Corp.
Via
GlobeNewswire
Tickers
ATNF
180 Life Sciences Corp. Announces Closing of $3 Million Registered Direct Offering and Concurrent Private Placement
April 10, 2023
From
180 Life Sciences Corp.
Via
GlobeNewswire
Tickers
ATNF
180 Life Sciences Corp. Announces $3 Million Registered Direct Offering and Concurrent Private Placement
April 05, 2023
From
180 Life Sciences Corp.
Via
GlobeNewswire
Tickers
ATNF
180 Life Sciences Announces Presentation at the Gordon Conference
February 27, 2023
From
180 Life Sciences Corp.
Via
GlobeNewswire
Tickers
ATNF
180 Life Sciences Announces Allowance of Claims for a US Patent for Dupuytren’s Disease Treatment and Application
February 23, 2023
From
180 Life Sciences Corp.
Via
GlobeNewswire
Tickers
ATNF
180 Life Sciences Provides Update Regarding Anti-TNF Frozen Shoulder Trial
February 22, 2023
From
180 Life Sciences Corp.
Via
GlobeNewswire
Tickers
ATNF
180 Life Sciences Announces Publication of a Review on the Treatments for Early Stage Dupuytren’s Disease
January 25, 2023
From
180 Life Sciences Corp.
Via
GlobeNewswire
Tickers
ATNF
180 Life Sciences Engages Kinexum for Assistance in Applying for Marketing Authorisation in the United Kingdom
January 17, 2023
From
180 Life Sciences Corp.
Via
GlobeNewswire
Tickers
ATNF
180 Life Sciences Regains Full Compliance with Nasdaq Minimum Bid Price Requirement
January 05, 2023
From
180 Life Sciences Corp.
Via
GlobeNewswire
Tickers
ATNF
180 Life Sciences Announces Publication of a Review on the Biological Basis of Dupuytren’s Disease
January 04, 2023
From
180 Life Sciences Corp.
Via
GlobeNewswire
Tickers
ATNF
180 Life Sciences Corp. CEO James Woody, MD, PhD Issues Letter to Shareholders
December 29, 2022
From
180 Life Sciences Corp.
Via
GlobeNewswire
Tickers
ATNF
180 Life Sciences Corp. Announces Closing of $6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
December 23, 2022
From
180 Life Sciences Corp.
Via
GlobeNewswire
Tickers
ATNF
180 Life Sciences Corp. Announces $6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
December 20, 2022
From
180 Life Sciences Corp.
Via
GlobeNewswire
Tickers
ATNF
180 Life Sciences Corp. Announces 1-for 20 Reverse Stock Split as Part of Nasdaq Compliance Plan
December 16, 2022
From
180 Life Sciences Corp.
Via
GlobeNewswire
Tickers
ATNF
180 Life Sciences Provides Update on Progress To Seek Medicines and Healthcare Products Regulatory Agency Marketing Authorization for Anti-TNF Treatment of Early Stage Dupuytren’s Contracture
November 30, 2022
From
180 Life Sciences Corp.
Via
GlobeNewswire
Tickers
ATNF
180 Life Sciences to Participate in A.G.P.’s Virtual Biotech Conference to be Held November 30 – December 1, 2022
November 21, 2022
From
180 Life Sciences Corp.
Via
GlobeNewswire
Tickers
ATNF
CORRECTION: Adalimumab Found To Be A Likely Cost-Effective Treatment for Early-Stage Dupuytren’s Disease
November 15, 2022
From
180 Life Sciences Corp.
Via
GlobeNewswire
Tickers
ATNF
Adalimumab Found To Be A Likely Cost-Effective Treatment for Early-Stage Dupuytren’s Disease
November 15, 2022
From
180 Life Sciences Corp.
Via
GlobeNewswire
Tickers
ATNF
180 Life Sciences Announces That the University of Oxford Has Been Awarded a Grant From the National Institute for Health and Care Research in the U.K. to Conduct a Clinical Trial in Post Operative Delirium/Cognitive Deficit in a Jointly Funded Program
July 27, 2022
From
180 Life Sciences Corp.
Via
GlobeNewswire
Tickers
ATNF
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.